Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Protein expression in CD138 plasma cells predicts prognosis in MM patients

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.06.18
Views: 2319

Dr Irena Misiewicz-Krzeminska - Cancer Research Center, Salamanca, Spain

Dr Misiewicz-Krzeminska speaks with ecancer at EHA 23 about the utility of proteins expressed within the plasma cells of patients with multiple myeloma who have been treated with VRD chemotherapy as prognostic factors for disease relapse and vulnerability.

From samples collected in previous trials, she describes the expression levels of proteins including ikaros and cyclin D as highly indicative of treatment susceptibility and suitability in patients, and a potential predictive factor to the disease in case of relapse.

These findings could lead to simple screening of patients in the near future, with no barrier to availability beyond training and education in the technique.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.


EHA 2018

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation